Barings LLC Makes New $173,000 Investment in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Barings LLC acquired a new position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,933 shares of the company’s stock, valued at approximately $173,000.

Other hedge funds also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its position in shares of Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after acquiring an additional 137 shares during the period. Venturi Wealth Management LLC acquired a new position in shares of Dr. Reddy’s Laboratories in the 3rd quarter worth approximately $60,000. Van ECK Associates Corp raised its holdings in shares of Dr. Reddy’s Laboratories by 64.3% in the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after buying an additional 322 shares in the last quarter. POM Investment Strategies LLC raised its holdings in shares of Dr. Reddy’s Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after buying an additional 1,820 shares in the last quarter. Finally, Glenmede Trust Co. NA acquired a new position in shares of Dr. Reddy’s Laboratories in the 3rd quarter worth approximately $207,000. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Trading Down 0.5 %

RDY stock opened at $12.93 on Friday. The business has a fifty day moving average price of $14.18 and a 200 day moving average price of $14.94. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $12.62 and a fifty-two week high of $16.89. The stock has a market capitalization of $10.79 billion, a price-to-earnings ratio of 20.59 and a beta of 0.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. StockNews.com cut Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.